Who Paid My Doc
Marc Pfeffer
Cardiovascular Disease Boston, MA Medical Doctor
NPI 1598703860 CMS profile 343956
75 Francis Street, Brigham & Women's Hosp, Boston, MA 02115
General payments
$164,776
Research payments
$1,800
Ownership & investment interest
$0
Research they led as principal investigator
$779,954
Through program year 2025, Marc Pfeffer of Boston, MA is reported in the CMS Open Payments database as having received $164,776 across 112 general payments and $1,800 in research payments paid to them. Separately, studies naming them as principal investigator received $779,954 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $19,113 | 10 | |
| 2024 | General | $14,722 | 6 | |
| 2023 | General | $3,188 | 2 | |
| 2022 | General | $10,620 | 7 | |
| 2022 | Research | $1,800 | 1 | |
| 2021 | General | $13,975 | 8 | |
| 2020 | General | $39,860 | 16 | |
| 2019 | General | $63,299 | 63 |
Beside peers
- Marc Pfeffer
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Marc Pfeffer were reported at $19,113. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Marc Pfeffer | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $63,299 | $450 | $127–$1,392 | $163 |
| 2020 | $39,860 | $242 | $77–$751 | $114 |
| 2021 | $13,975 | $335 | $101–$1,037 | $132 |
| 2022 | $10,620 | $395 | $121–$1,211 | $149 |
| 2023 | $3,188 | $443 | $136–$1,283 | $160 |
| 2024 | $14,722 | $450 | $136–$1,323 | $164 |
| 2025 | $19,113 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
113 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Massachusetts
Marc Sabatine
Cardiovascular Disease · Boston, MA
Elizabeth Nabel
Cardiovascular Disease · Boston, MA
Kenneth Rosenfield
Cardiovascular Disease · Boston, MA
Kevin Croce
Cardiovascular Disease · Chestnut Hill, MA
James Januzzi
Cardiovascular Disease · Boston, MA
Muthiah Vaduganathan
Cardiovascular Disease · Boston, MA
Related records
Cardiovascular Disease in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.